Results 101 to 110 of about 84,688 (355)

Intravenous lanadelumab for the treatment of moderately ill COVID‐19 patients

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Kallikrein‐kinin system (KKS) dysregulation is hypothesized to play a pathogenetic role in COVID‐19‐associated pulmonary oedema. To investigate the efficacy and safety of intravenous lanadelumab, a monoclonal antibody that inhibits plasma kallikrein, in COVID‐19, we conducted a phase 2, open‐label, randomized‐controlled, proof‐of‐concept ...
Job J. Engel   +12 more
wiley   +1 more source

Autonomic regulation therapy to enhance myocardial function in heart failure patients: the ANTHEM-HFpEF study. [PDF]

open access: yes, 2017
BackgroundApproximately half of the patients presenting with new-onset heart failure (HF) have HF with preserved left ventricular ejection fraction (HFpEF) and HF with mid-range left ventricular ejection fraction (HFmrEF).
Amurthur, Badri   +8 more
core   +1 more source

The Prevalence and Implications of Polypharmacy in Individuals With Type 1 Diabetes

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Polypharmacy is increasingly recognized as a relevant issue in diabetes care, but its prevalence and clinical relevance in individuals with type 1 diabetes remain underexplored. This study aimed to determine the prevalence of polypharmacy and to identify associated clinical and psychological factors. Participants were recruited from a tertiary diabetes
Namam Ali   +4 more
wiley   +1 more source

A role for the brain RAS in Alzheimer's and Parkinson's diseases

open access: yesFrontiers in Endocrinology, 2013
The brain renin-angiotensin system (RAS) has available the necessary functional components to produce the active ligands angiotensins II, III, IV, angiotensin (1-7), and angiotensin (3-7).
John William Wright   +2 more
doaj   +1 more source

Natriuretic peptides and cardiovascular damage in the metabolic syndrome. Molecular mechanisms and clinical implications [PDF]

open access: yes, 2010
Natriuretic peptides are endogenous antagonists of vasoconstrictor and salt- and water-retaining systems in the body's defence against blood pressure elevation and plasma volume expansion, through direct vasodilator, diuretic and natriuretic properties ...
ALONZO, ALESSANDRO   +4 more
core   +1 more source

Characterizing Alzheimer’s Disease and Related Dementia in a Hypertension Population Within the State of Florida Using Electronic Health Record–Based Data

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Hypertension is a known modifiable risk factor for Alzheimer’s disease and related dementia (ADRD). However, it is unknown how variance in hypertension control, antihypertensive medications, and social determinants of health, such as social deprivation index (SDI), influence the risk of developing ADRD.
Eissa A. Jafari   +6 more
wiley   +1 more source

Intraoperative angioedema induced by angiotensin II receptor blocker: a case report

open access: yesPatient Safety in Surgery, 2018
Background Angiotensin II receptor blockers are a class of antihypertensive agent that is developed to exclude the adverse effects of angiotensin converting enzyme inhibitors.
Ala”a Alhowary   +3 more
doaj   +1 more source

The role of endothelin-1 in pulmonary arterial hypertension. [PDF]

open access: yes, 2014
Pulmonary arterial hypertension (PAH) is a rare but debilitating disease, which if left untreated rapidly progresses to right ventricular failure and eventually death. In the quest to understand the pathogenesis of this disease differences in the profile,
Chester, AH, Yacoub, MH
core   +1 more source

Cardiovascular‐Kidney‐Metabolic Syndrome in People With HIV: An Emerging Frontier for Clinical Pharmacology

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
As antiretroviral therapy (ART) prolongs lifespans, people with HIV (PWH) face a new syndemic: Cardiovascular‐Kidney‐Metabolic (CKM) syndrome. Yet CKM in PWH is poorly characterized. Inflammation, complex pharmacokinetic (PK) alterations, ART‐associated metabolic effects, and gut dysbiosis amplify risk. Managing CKM increases medication burden, thereby
Aaron S. Devanathan, Thomas D. Nolin
wiley   +1 more source

Home - About - Disclaimer - Privacy